Tirzepatide for weight loss in people with atrial fibrillation
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the heart rhythm condition atrial fibrillation. If you have AFib and are overweight or obese, this trial may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your body mass index (BMI) is between 27 and 60.
- You have been diagnosed with atrial fibrillation that causes symptoms, and it is either occasional (paroxysmal) or persistent.
- You are not currently taking any GLP-1 or similar weight-loss medications, and have not used them in the last 6 months.
- You are able and willing to inject the medication yourself.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tirzepatide, a medication for weight and blood sugar, can reduce the chances of atrial fibrillation (an irregular heartbeat) coming back after a heart procedure called catheter ablation in people with overweight or obesity. It may help by addressing weight-related factors that contribute to heart rhythm problems.
This trial tests whether tirzepatide, a weight-loss and blood-sugar medication, can help prevent atrial fibrillation (AFib) from coming back after a catheter ablation procedure. The study focuses on people with obesity or overweight and heart problems, particularly those with a stiff heart (HFpEF).
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.